Claims for Patent: 5,837,464

Summary for Patent: 5,837,464

Title:	Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
Abstract:	This invention provides a method for determining susceptibility for an anti-viral drug comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell; and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-viral drug, wherein a test concentration of the anti-viral drug is present at steps (a)-(c); at steps (b)-(c); or at step (c). This invention also provides a method for determining anti-viral drug resistance in a patient comprising: (a) determining anti-viral drug susceptibility in the patient at a first time using the susceptibility test described above, wherein the patient-derived segment is obtained from the patient at about said time; (b) determining anti-viral drug susceptibility of the same patient at a later time; and (c) comparing the anti-viral drug susceptibilities determined in step (a) and (b), wherein a decrease in anti-viral drug susceptibility at the later time compared to the first time indicates development or progression of anti-viral drug resistance in the patient. This invention also provides a method for evaluating the biological effectiveness of a candidate anti-viral drug compound. Compositions including resistance test vectors comprising a patient-derived segment and an indicator gene and host cells transformed with the resistance test vectors are provided.
Inventor(s):	Capon; Daniel (Hillsborough, CA), Petropoulos; Christos J. (Half Moon Bay, CA)
Assignee:	ViroLogic, Inc. (S. San Francisco, CA)
Application Number:	08/790,963
Patent Claims:	1. A method for determining susceptibility for an anti-HIV drug comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell, wherein the expression of the indicator gene is dependent upon the patient-derived segment; and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-HIV drug, wherein a test concentration of the anti-HIV drug is present at steps (a)-(c); at steps (b)-(c); or at step (c). 2. The method of claim 1, wherein the resistance test vector comprises DNA of a genomic viral vector. 3. The method of claim 1, wherein the resistance test vector comprises DNA of a subgenomic viral vector. 4. A method for determining anti-HIV drug resistance in a patient comprising: (a) developing a standard curve of drug susceptibility for an anti-HIV drug; (b) determining anti-HIV drug susceptibility in the patient according to the method of claim 1; and (c) comparing the anti-HIV drug susceptibility in step (b) with the standard curve determined in step (a), wherein a decrease in anti-HIV susceptibility indicates development of anti-HIV drug resistance in the patient. 5. The method of claim 1, wherein the resistance test vector comprises DNA of HIV. 6. The method of claim 5, wherein the resistance test vector comprises DNA encoding vif, vpr, tat, rev, vpu, and nef. 7. The method of claim 1, wherein the patient-derived segment comprises a functional viral sequence. 8. The method of claim 1, wherein the patient-derived segment encodes one protein that is the target of an anti-HIV drug. 9. The method of claim 1, wherein the patient-derived segment encodes two or more proteins that are the targets of one or more anti-HIV drugs. 10. A method for determining anti-HIV drug resistance in a patient comprising: (a) determining anti-HIV drug susceptibility in the patient at a first time according to the method of claim 1, wherein the patient-derived segment is obtained from the patient at about said time; (b) determining anti-HIV drug susceptibility of the same patient at a later time; and (c) comparing the anti-HIV drug susceptibilities determined in step (a) and (b), wherein a decrease in anti-HIV drug susceptibility at the later time compared to the first time indicates development or progression of anti-HIV drug resistance in the patient. 11. The method of claim 1, wherein the patient-derived segment comprises an HIV gene. 12. The method of claim 11, wherein the patient-derived segment comprises an HIV gag-pol gene. 13. The method of claim 1, wherein the indicator gene is a functional indicator gene and the host cell is a resistance test vector host cell, including the additional step of infecting the target host cell with resistance test vector viral particles using filtered supernatants from said resistance test vector host cells. 14. The method of claim 1, wherein the indicator gene is a non-functional indicator gene. 15. The method of claim 14, wherein the host cell is a packaging host cell/resistance test vector host cell. 16. The method of claim 15, wherein the culturing is by co-cultivation. 17. The method of claim 15, wherein the target host cell is infected with resistance test vector viral particles using filtered supernatants from said packaging host cell/resistance test vector host cells. 18. The method of claim 1, wherein the indicator gene is a luciferase gene. 19. The method of claim 1, wherein the indicator gene is an E. coli lacZ gene. 20. The method of claim 15, wherein the packaging host cell/resistance test vector host cell is a human cell. 21. The method of claim 15, wherein the packaging host cell/resistance test vector host cell is a human embryonic kidney cell. 22. The method of claim 15, wherein the packaging host cell/resistance test vector host cell is a 293 cell. 23. The method of claim 1, wherein the target host cell is a human T cell. 24. The method of claim 1, wherein the target host cell is a human T cell leukemia cell line. 25. The method of claim 1, wherein the target host cell is a Jurkat cell line. 26. The method of claim 1, wherein the target host cell is a H9 cell line. 27. The method of claim 1, wherein the target host cell is a CEM cell line. 28. The method of claim 1, wherein the target host cell is a human embryonic kidney cell. 29. The method of claim 1, wherein the target host cell is a 293 cell. 30. A resistance test vector comprising an HIV patient-derived segment and an indicator gene, wherein the expression of the indicator gene is dependent upon the patient-derived segment. 31. The resistance test vector of claim 30, wherein the patient-derived segment encodes one protein that is the target of an anti-HIV drug. 32. The resistance test vector of claim 30, wherein the patient-derived segment encodes two or more proteins that are the targets of one or more anti-HIV drugs. 33. The resistance test vector of claim 30, wherein the patient-derived segment comprises an HIV gene. 34. The resistance test vector of claim 30, wherein the patient-derived segment comprises DNA of HIV. 35. The resistance test vector of claim 34, wherein the patient-derived segment comprises DNA encoding vif, vpr tat, rev, vpu, and nef. 36. The resistance test vector of claim 33, wherein the patient-derived segment comprises an HIV gag-pol gene. 37. The resistance test vector of claim 30, wherein the indicator gene is a functional indicator gene. 38. The resistance test vector of claim 30, wherein the indicator gene is a non-functional indicator gene. 39. The resistance test vector of claim 30, wherein the indicator gene is a luciferase gene. 40. A packaging host cell transfected with a resistance test vector of claim 30. 41. The packaging host cell of claim 40 that is a mammalian host cell. 42. The packaging host cell of claim 40 that is a human host cell. 43. The packaging host cell of claim 40 that is a human embryonic kidney cell. 44. The packaging host cell of claim 40 that is 293 cells. 45. The resistance test vector of claim 30 comprising an indicator gene viral vector and a packaging vector said indicator gene viral vector comprising an indicator gene and said packaging vector comprising a patient-derived segment. 46. A method for determining susceptibility for an anti-HIV drug comprising: (a) introducing a resistance test vector comprising a patient-derived segment and a nonfunctional indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell, wherein the expression of the indicator gene is dependent upon the patient-derived segment; and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-HIV drug, wherein a test concentration of the anti-HIV drug is present at steps (a)-(c); at steps (b)-(c); or at step (c). 47. The method of claim 46, wherein the resistance test vector comprises DNA of a genomic viral vector. 48. The method of claim 46, wherein the resistance test vector comprises DNA of a subgenomic viral vector. 49. The method of claim 46, wherein the resistance test vector comprises DNA of HIV. 50. The method of claim 49, wherein the resistance test vector comprises DNA encoding vif, vpr, tat, rev, vpu, and nef. 51. The method of claim 46, wherein the patient-derived segment encodes one protein that is the target of an anti-HIV drug. 52. The method of claim 46, wherein the patient-derived segment encodes two or more proteins that are the targets of one or more anti-HIV drugs. 53. The method of claim 46, wherein the patient-derived segment comprises an HIV gene. 54. The method of claim 53, wherein the patient-derived segment comprises an HIV gag-pol gene. 55. The method of claim 46, wherein the indicator gene is a luciferase gene. 56. The method of claim 46, wherein the host cell is a packaging host cell. 57. The method of claim 46, wherein the packaging host cell is a human cell. 58. The method of claim 46, wherein the packaging host cell is a human embryonic kidney cell. 59. The method of claim 46, wherein the packaging host cell is a 293 cell. 60. The method of claim 46, wherein the nonfunctional indicator gene comprises a permuted promoter. 61. The method of claim 46, wherein the nonfunctional indicator gene comprises a permuted coding region. 62. The method of claim 46, wherein the nonfunctional indicator gene comprises an inverted intron. 63. The method of claim 46, wherein the host cell and target host cell are the same cell. 64. The method of claim 46, wherein the target host cell is a human cell. 65. The method of claim 46, wherein the target host cell is a human T cell. 66. The method of claim 46, wherein the target host cell is a human embryonic kidney cell. 67. The method of claim 46, wherein the target host cell is a 293 cell. 68. The method of claim 46, wherein the target host cell is infected with resistance test vector viral particles using filtered supernatants from said packaging host cell/resistance test vector host cell. 69. The method of claim 46, wherein said culturing is by co-cultivation. 70. A method for determining anti-HIV drug resistance in a patient comprising: (a) developing a standard curve of drug susceptibility for an anti-HIV drug; (b) determining anti-HIV drug susceptibility in the patient according to the method of claim 46; and (c) comparing the anti-HIV drug susceptibility in step (b) with the standard curve determined in step (a), wherein a decrease in anti-HIV susceptibility indicates development of anti-HIV drug resistance in the patient. 71. A method for determining anti-HIV drug resistance in a patient comprising: (a) determining anti-HIV drug susceptibility in the patient at a first time according to the method of claim 46, wherein the patient-derived segment is obtained from the patient at about said time; (b) determining anti-HIV drug susceptibility of the same patient at a later time; and (c) comparing the anti-HIV drug susceptibilities determined in steps (a) and (b), wherein a decrease in anti-HIV drug susceptibility at the later time compared to the first time indicates development or progression of anti-HIV drug resistance in the patient. 72. A method for evaluating the biological effectiveness of a candidate anti-HIV drug compound comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from step (a); (c) measuring expression of the indicator gene in a target host cell, wherein the expression of the indicator gene is dependent upon the patient- derived segment; and (d) comparing the expression of the indicator gene from step (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the candidate anti-HIV drug compound, wherein a test concentration of the candidate anti-HIV drug compound is present at steps (a)-(c); at steps (b)-(c); or at step (c). 73. The method of claim 72, wherein the resistance test vector comprises DNA of HIV. 74. The method of claim 72, wherein the resistance test vector comprises DNA encoding HIV gag-pol. 75. The method of claim 72, wherein the patient-derived segment encodes one protein that is the target of an anti-HIV drug. 76. The method of claim 72, wherein the patient-derived segment encodes two or more proteins that are the targets of one or more anti-HIV drugs. 77. The method of claim 72, wherein the patient-derived segment comprises an HIV gene. 78. A method for determining susceptibility for an anti-HIV drug comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator into a host cell; (b) culturing the host cell from (a); (c) measuring the indicator in a target host cell, wherein a change in the indicator is dependent upon the patient-derived segment; and (d) comparing the measurement of the indicator from (c) with the measurement of the indicator when steps (a)-(c) are carried out in the absence of the anti-HIV drug, wherein a test concentration of the anti-HIV drug is present at steps (a)-(c); at steps (b)-(c); or at step (c). 79. The method of claim 78, wherein the indicator comprises a DNA structure. 80. The method of claim 78, wherein the indicator comprises a RNA structure. 81. A method for evaluating the biological effectiveness of a candidate anti-HIV drug compound comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator into a host cell; (b) culturing the host cell from step (a); (c) measuring the indicator in a target host cell, wherein a change in the indicator is dependent upon the patient-derived segment; and (d) comparing the measurement of the indicator from step (c) with the measurement of the indicator measured when steps (a)-(c) are carried out in the absence of the candidate anti-HIV drug compound, wherein a test concentration of the candidate anti-HIV drug compound is present at steps (a)-(c); at steps (b)-(c); or at step (c). 82. The method of claim 81, wherein the indicator comprises a DNA structure. 83. The method of claim 82, wherein the indicator comprises a RNA structure .

Details for Patent 5,837,464

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26